| scholarly article | Q13442814 |
| P50 | author | Sten Rasmussen | Q39182288 |
| Flemming W. Bach | Q39378531 | ||
| P2093 | author name string | Lars Arendt-Nielsen | |
| Parisa Gazerani | |||
| Ali Karshenas | |||
| Larissa Bittencourt da Silva | |||
| P2860 | cites work | Botulinum toxin for myofascial pain syndromes in adults | Q24199156 |
| The capsaicin receptor: a heat-activated ion channel in the pain pathway | Q24322558 | ||
| Statistics review 4: sample size calculations | Q24798787 | ||
| Activation of peripheral NMDA receptors contributes to human pain and rat afferent discharges evoked by injection of glutamate into the masseter muscle | Q27863767 | ||
| Regulation of calcitonin gene-related peptide secretion from trigeminal nerve cells by botulinum toxin type A: implications for migraine therapy | Q28246355 | ||
| Calcitonin gene-related peptide is a potent vasodilator | Q28306967 | ||
| Capsaicin-evoked CGRP release from rat buccal mucosa: development of a model system for studying trigeminal mechanisms of neurogenic inflammation | Q28362807 | ||
| Peripheral metabotropic glutamate receptors as drug targets for pain relief | Q30722206 | ||
| Microdialysis of the interstitial water space in human skin in vivo: quantitative measurement of cutaneous glucose concentrations | Q31056995 | ||
| Botulinum toxin type A reduces capsaicin-evoked pain and neurogenic vasodilatation in human skin | Q33267854 | ||
| Subcutaneous Botulinum toxin type A reduces capsaicin-induced trigeminal pain and vasomotor reactions in human skin | Q33384053 | ||
| Glutamate and substance P coexist in primary afferent terminals in the superficial laminae of spinal cord | Q33658035 | ||
| OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program | Q34116531 | ||
| Botulinum toxin A and the cutaneous nociception in humans: a prospective, double-blind, placebo-controlled, randomized study | Q78454731 | ||
| AAPS-FDA Workshop White Paper: microdialysis principles, application, and regulatory perspectives | Q80177901 | ||
| Botulinum toxin A does not alter capsaicin-induced pain perception in human skin | Q80270122 | ||
| Botulinum toxin type A for the prophylactic treatment of chronic daily headache: a randomized, double-blind, placebo-controlled trial | Q81248679 | ||
| Botulinum toxin type A in experimental neuropathic pain | Q81290805 | ||
| Botulinum toxin type A for the treatment of trigeminal neuralgia: results from a randomized, double-blind, placebo-controlled trial | Q83856423 | ||
| OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial | Q84582635 | ||
| Subcutaneous injection of botulinum toxin a is beneficial in postherpetic neuralgia | Q48306948 | ||
| Elevation of the Extracellular Concentrations of Glutamate and Aspartate in Rat Hippocampus During Transient Cerebral Ischemia Monitored by Intracerebral Microdialysis | Q48609930 | ||
| Development of inflammation after application of mustard oil or glutamate to the rat temporomandibular joint. | Q50519879 | ||
| In situ microdialysis in tendon tissue: high levels of glutamate, but not prostaglandin E2 in chronic Achilles tendon pain. | Q51422267 | ||
| Inhibition of release of neurotransmitters from rat dorsal root ganglia by a novel conjugate of a Clostridium botulinum toxin A endopeptidase fragment and Erythrina cristagalli lectin. | Q52861424 | ||
| The effects of Botulinum Toxin type A on capsaicin-evoked pain, flare, and secondary hyperalgesia in an experimental human model of trigeminal sensitization | Q60190513 | ||
| Acute Effects of Substance P and Calcitonin Gene-Related Peptide in Human Skin – A Microdialysis Study | Q60678317 | ||
| Plasma extravasation and neuropeptide release in human skin as measured by intradermal microdialysis | Q60678327 | ||
| Botulinum toxin in the treatment of myofascial pain syndrome | Q60776960 | ||
| Pain, hyperalgesia and activity in nociceptive C units in humans after intradermal injection of capsaicin | Q68136348 | ||
| The origin, structure, and pharmacological activity of botulinum toxin | Q72518481 | ||
| Sensitivity of embryonic rat dorsal root ganglia neurons to Clostridium botulinum neurotoxins | Q73426186 | ||
| Enkephalin and aFGF are differentially regulated in rat spinal motoneurons after chemodenervation with botulinum toxin | Q73466389 | ||
| Presynaptic effects of botulinum toxin type A on the neuronally evoked response of albino and pigmented rabbit iris sphincter and dilator muscles | Q73544372 | ||
| A microdialysis method allowing characterization of intercellular water space in humans | Q34185788 | ||
| Botulinum toxin A in the treatment of headache syndromes and pericranial pain syndromes | Q34199058 | ||
| Peripheral excitatory amino acids | Q34442040 | ||
| Botulinum toxin type A induces direct analgesic effects in chronic neuropathic pain | Q34785937 | ||
| A focused review of the use of botulinum toxins for low back pain | Q35060564 | ||
| A focused review on the use of botulinum toxins for neuropathic pain | Q35060570 | ||
| Evidence for antinociceptive activity of botulinum toxin type A in pain management | Q35187501 | ||
| Synaptic transmission: inhibition of neurotransmitter release by botulinum toxins | Q35187504 | ||
| Botulinum toxin in clinical practice | Q35807826 | ||
| Review of a proposed mechanism for the antinociceptive action of botulinum toxin type A. | Q36185790 | ||
| Unravelling the mystery of capsaicin: a tool to understand and treat pain | Q36293653 | ||
| Nonlinear relationship between level of blood flow and skin temperature for different dynamics of temperature change. | Q36632120 | ||
| The structure and mode of action of different botulinum toxins | Q36656462 | ||
| Sensitization, glutamate, and the link between migraine and fibromyalgia | Q36951346 | ||
| Capsaicin: cellular targets, mechanisms of action, and selectivity for thin sensory neurons | Q37182629 | ||
| Microdialysis--principles and applications for studies in animals and man. | Q37385761 | ||
| Time course analysis of the effects of botulinum neurotoxin type A on pain and vasomotor responses evoked by glutamate injection into human temporalis muscles | Q37617800 | ||
| Updates on the antinociceptive mechanism hypothesis of botulinum toxin A. | Q37945809 | ||
| A randomized, double-blind, placebo controlled study on analgesic effects of botulinum toxin A. | Q39389210 | ||
| Botulinum Toxin A reduces neurogenic flare but has almost no effect on pain and hyperalgesia in human skin. | Q39398067 | ||
| Localized injections of botulinum toxin for the treatment of focal dystonia and hemifacial spasm | Q39539908 | ||
| Double-blind study of botulinum toxin in spasmodic torticollis | Q39542317 | ||
| Neurogenic vasodilatation and plasma leakage in the skin | Q41697768 | ||
| Evidence that glutamate is released from capsaicin-sensitive primary afferent fibers in rats: study with on-line continuous monitoring of glutamate | Q42275528 | ||
| Regulation of calcitonin gene-related peptide secretion by a serotonergic antimigraine drug | Q42470935 | ||
| Interstitial glutamate concentration is elevated in the masseter muscle of myofascial temporomandibular disorder patients | Q42768754 | ||
| Botulinum neurotoxin type A (BoNTA) decreases the mechanical sensitivity of nociceptors and inhibits neurogenic vasodilation in a craniofacial muscle targeted for migraine prophylaxis | Q42930213 | ||
| Glutamate-induced sensitization of rat masseter muscle fibers | Q43860491 | ||
| TRPV3 is a calcium-permeable temperature-sensitive cation channel. | Q44037373 | ||
| Contribution of peripheral NMDA receptors in craniofacial muscle nociception and edema formation | Q44506350 | ||
| Subcutaneous administration of botulinum toxin A reduces formalin-induced pain | Q44722571 | ||
| Cerebrospinal fluid glutamate levels in chronic migraine | Q45021407 | ||
| Increase in muscle nociceptive substances and anaerobic metabolism in patients with trapezius myalgia: microdialysis in rest and during exercise | Q45160892 | ||
| Botulinum toxin for diabetic neuropathic pain: a randomized double-blind crossover trial | Q46107474 | ||
| Antinociceptive effect of botulinum toxin type a in rat model of carrageenan and capsaicin induced pain. | Q46453921 | ||
| A lack of antinociceptive or antiinflammatory effect of botulinum toxin A in an inflammatory human pain model | Q46905369 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 3 | |
| P304 | page(s) | 126-132 | |
| P577 | publication date | 2014-05-01 | |
| P1433 | published in | Pain Research & Management | Q7124815 |
| P1476 | title | Blockade of glutamate release by botulinum neurotoxin type A in humans: a dermal microdialysis study | |
| P478 | volume | 19 |
| Q55080639 | Antipruritic Effects of Botulinum Neurotoxins. |
| Q26781281 | Botulinum Toxin Type a as a Therapeutic Agent against Headache and Related Disorders |
| Q28084583 | Botulinum Toxin as a Pain Killer: Players and Actions in Antinociception |
| Q92455068 | Mechanisms of Botulinum Toxin Type A Action on Pain |
Search more.